## Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Pacira Pharr	naceuticals, Inc.									
Form 4										
June 07, 201								OMB A	PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								3235-0287		
Check th if no lon	ger							Expires:	January 31,	
subject t Section	16. <b>SIAIE</b>	MENT O	OF CHANGES IN BENEFICIAL OV SECURITIES				VNERSHIP OF	Estimated burden hor	urs per	
Form 5 obligation may con See Instr 1(b).	Filed put ons Section 170	(a) of the l	Public U	Jtility Hol		y Act o	ge Act of 1934, of 1935 or Sectio 940	response	. 0.5	
(Print or Type	Responses)									
STACK DAVID M Syn			Symbol	2. Issuer Name <b>and</b> Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX			5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (	(Middle)				FUIX	(Cheo	ck all applicabl	e)	
C/O PACIRA PHARMACEUTICALS, INC., 5			<ul><li>3. Date of Earliest Transaction</li><li>(Month/Day/Year)</li><li>06/05/2012</li></ul>				X Director 10% Owner X Officer (give title Other (specify below) below) President and CEO			
SYLVAN	WAY, SUITE 10	5								
				4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ul>			
PARSIPPA	NY, NJ 07054						Form filed by M Person	More than One R	eporting	
(City)	(State)	(Zip)	Tal	ble I - Non-I	Derivative Secu	rities Ac	cquired, Disposed o	f, or Beneficia	illy Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	4. Securities nAcquired (A) of Disposed of (E (Instr. 3, 4 and (A) or	or 1) 5)	SecuritiesIBeneficially(Owned(Following(Reported(Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V		Price	(Instr. 3 and 4)			
Reminder: Rej	port on a separate line	e for each cl	lass of sec	urities benef	ficially owned d	irectly or	r indirectly.			
					information required te	n conta o respo	bond to the collect nined in this form nd unless the for tly valid OMB cor	are not m	SEC 1474 (9-02)	
	Tab				uired, Dispose , options, conv		Beneficially Owned ecurities)			
		nsaction Dat h/Day/Year)		eemed tion Date, if	4. 5. TransactionDe	Number erivative	of 6. Date Exer Expiration D		7. Title and Amount of Underlying Securities	

## Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) of Disposed of (D (Instr. 3, 4, and 5)	<b>)</b> )		(Instr. 3 and 4)	
				Code V	(A) (E	) Date Exercisable	Expiration Date	Title	Amount o Number o Shares
Common Stock	\$ 10.81	06/05/2012		А	350,000	<u>(1)</u>	06/04/2022	Common Stock	350,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
I G G G G G G G G G G G G G G G G G G G	Director	10% Owner	Officer	Other		
STACK DAVID M C/O PACIRA PHARMACEUTICALS, INC. 5 SYLVAN WAY, SUITE 100 PARSIPPANY, NJ 07054	х		President and CEO			
Signatures						
/s/ James Scibetta, by power of attorney	06/07/2012					
**Signature of Reporting Person	Date					

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests and becomes exercisable as to 25% of the option shares on June 5, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.